Artur Chabowski resigned from the position of President of Mabion, a Polish biotechnology company. It will come into force on 30 June.
Artur Chabowski: My mission fulfilled
Artur Chabowski’s decision is related to the completion of one of the key steps towards the registration of the biosimilar MabionCD20 in Europe. “I feel that my mission has been fulfilled and that the company itself is now in a very good shape” – said Chabowski quoted in the communiqué.
This key step is the submission of answers to questions from the European Medicines Agency (EMA). This allows for the continuation of the registration procedure in the European Union. The EMA is currently verifying the answers submitted by the company. Mabion expects the next round of questions in about two months.
New president of Mabion until 30th June
Artur Chabowski has been with Mabion since 2009. He has held the position of president since December 2016. Previously, he was a member of the board of directors and a member of the supervisory board of the company.
Mabion announced in a press release that it had already begun the process of seeking a new president. He will be faced with a number of key tasks. The first is the launch of three new biosimilar drug projects, which are scheduled for the second half of 2019. In addition, the clinical development of MabionMS is planned. The company also wants to register MabionCD20 in the US.
The target structure of the management board, including the division of competences, will be presented by 30 June.